Home » Newsletters » BioWorld Science

BioWorld Science

June 13, 2016

View Archived Issues

Kalvista Pharmaceuticals patents KLKB1 inhibitors

Novo Nordisk discloses GLP-1 receptor agonists

Acturum Life Science describes mPGES-1 inhibitors

FDA approves Vaxchora cholera vaccine

FDA grants orphan drug designation to fosbretabulin

Cantargia finalizes tests for CAN-04 before applying for clinical trials

Hanmi Pharmaceutical launches olmutinib in South Korea

Yuhan's fibroblast growth factor 21 analogue YH-25348 displays good antidiabetic characteristics

Preliminary phase I data for milatuzumab

Zealand Pharma and Beta Bionics collaborate on new bionic pancreas system

Results from the DRIVE-PK study: treating anemia and hemolysis in pyruvate kinase deficient patients

Agilis gene therapy named FDA orphan drug for aromatic L-amino acid decarboxylase deficiency

Incyte initiates phase I/II study of INCB-057643 in advanced malignancies

BioTime announces a grant for further development of OpRegen

Favorable phase II data on Smac mimetic for primary myelofibrosis

Nexus BioPharma announces the completion of merger

Shire completes European decentralized procedure for immunoglobulin treatment Cuvitru

HDAC6 inhibitor ACY-241 tested in combination with pomalidomide and dexamethasone

FDA awards orphan drug designation to Galena Biopharma's cancer immunotherapy peptide programs

Knockout model reveals role of fibronectin extra domain A sepsis outcomes

Pharmacokinetics/pharmacodynamics of dapagliflozin in pediatric patients with type 2 diabetes

Dr. Reddy's to acquire portfolio of eight ANDAs from Teva

European research project investigates link between gut flora and Alzheimer's disease

Gla-300: meta-analysis of EDITION -1, -2 and -3 studies

FDA grants orphan drug designation to Herantis' recombinant human CDNF

Oral CC-486 well tolerated to date in nasopharyngeal cancer trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...